Abstract
Responsive neurostimulation (RNS) has been used to treat adults with medically refractory focal onset epilepsy with 1 to 2 seizure foci since its FDA approval in 2013.1,2 Due to its effectiveness and favorable safety profile, it is utilized for epilepsy in adults and off-label in pediatric populations.3,4 In this study, we analyze current trends in utilization of RNS therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
